{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T03:02:53Z","timestamp":1785380573319,"version":"3.55.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T00:00:00Z","timestamp":1587427200000},"content-version":"am","delay-in-days":325,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"National Institute of Health","award":["CA209818"],"award-info":[{"award-number":["CA209818"]}]},{"name":"National Institute of Health","award":["GM124046"],"award-info":[{"award-number":["GM124046"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.jconrel.2019.04.013","type":"journal-article","created":{"date-parts":[[2019,4,11]],"date-time":"2019-04-11T12:32:26Z","timestamp":1554985946000},"page":"109-116","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["Prevention of paclitaxel-induced neuropathy by formulation approach"],"prefix":"10.1016","volume":"303","author":[{"given":"Xiaowei","family":"Zang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Bong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran","family":"Deshpande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga B.","family":"Garbuzenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Minko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonid","family":"Kagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2019.04.013_bb0005","doi-asserted-by":"crossref","DOI":"10.1007\/s10928-018-9586-9","article-title":"Physiologically-based modeling and interspecies prediction of paclitaxel pharmacokinetics","author":"Zang","year":"2018","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"issue":"4","key":"10.1016\/j.jconrel.2019.04.013_bb0010","first-page":"252","article-title":"Cancer treatment and survivorship statistics, 2014","volume":"64","author":"DeSantis","year":"2014","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.jconrel.2019.04.013_bb0015","first-page":"1","article-title":"Persistent pain in cancer survivors: pathogenesis and treatment options","volume":"4","author":"Farquhar-Smith","year":"2016","journal-title":"Pain Clin. Updates XXIV"},{"key":"10.1016\/j.jconrel.2019.04.013_bb0020","doi-asserted-by":"crossref","first-page":"e553","DOI":"10.14694\/EdBook_AM.2015.35.e553","article-title":"Chemotherapy-induced peripheral neurotoxicity in cancer survivors: an underdiagnosed clinical entity?","author":"Cavaletti","year":"2015","journal-title":"Am. Soc. Clin. Oncol. Educ. Book."},{"issue":"4","key":"10.1016\/j.jconrel.2019.04.013_bb0025","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3109\/0284186X.2014.980912","article-title":"Peripheral neuropathy in colorectal cancer survivors: the influence of oxaliplatin administration. Results from the population-based PROFILES registry","volume":"54","author":"Beijers","year":"2015","journal-title":"Acta Oncol."},{"issue":"2","key":"10.1016\/j.jconrel.2019.04.013_bb0030","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(14)70251-0","article-title":"Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis","volume":"14","author":"Finnerup","year":"2015","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.jconrel.2019.04.013_bb0035","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2008.07558.x","article-title":"Therapy of chemotherapy-induced peripheral neuropathy","volume":"145","author":"Kaley","year":"2009","journal-title":"Br. J. Haematol."},{"issue":"4 Suppl 3","key":"10.1016\/j.jconrel.2019.04.013_bb0040","first-page":"16","article-title":"The clinical pharmacology of paclitaxel (Taxol)","volume":"20","author":"Rowinsky","year":"1993","journal-title":"Semin. Oncol."},{"issue":"9","key":"10.1016\/j.jconrel.2019.04.013_bb0045","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1021\/ja00738a045","article-title":"Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia","volume":"93","author":"Wani","year":"1971","journal-title":"J. Am. Chem. Soc."},{"issue":"15","key":"10.1016\/j.jconrel.2019.04.013_bb0050","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1093\/jnci\/82.15.1247","article-title":"Taxol: a novel investigational antimicrotubule agent","volume":"82","author":"Rowinsky","year":"1990","journal-title":"J. Natl. Cancer Inst."},{"issue":"3","key":"10.1016\/j.jconrel.2019.04.013_bb0055","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1073\/pnas.77.3.1561","article-title":"Taxol stabilizes microtubules in mouse fibroblast cells","volume":"77","author":"Schiff","year":"1980","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"22","key":"10.1016\/j.jconrel.2019.04.013_bb0060","doi-asserted-by":"crossref","first-page":"11887","DOI":"10.1016\/S0021-9258(19)68489-9","article-title":"Interactions of taxol, microtubule-associated proteins, and guanine nucleotides in tubulin polymerization","volume":"256","author":"Hamel","year":"1981","journal-title":"J. Biol. Chem."},{"issue":"5698","key":"10.1016\/j.jconrel.2019.04.013_bb0065","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/277665a0","article-title":"Promotion of microtubule assembly in vitro by taxol","volume":"277","author":"Schiff","year":"1979","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.jconrel.2019.04.013_bb0070","first-page":"31","article-title":"A new parenteral vehicle for the administration of some poorly water soluble anti-cancer drugs","volume":"41","author":"Tarr","year":"1987","journal-title":"J. Parenter. Sci. Technol."},{"issue":"3","key":"10.1016\/j.jconrel.2019.04.013_bb0075","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1021\/jm00107a042","article-title":"Biologically active taxol analogues with deleted A-ring side chain substituents and variable C-2\u2032 configurations","volume":"34","author":"Swindell","year":"1991","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.jconrel.2019.04.013_bb0080","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1093\/jnci\/83.4.288","article-title":"Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol","volume":"83","author":"Ringel","year":"1991","journal-title":"J. Natl. Cancer Inst."},{"issue":"1","key":"10.1016\/j.jconrel.2019.04.013_bb0085","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1021\/jm00079a019","article-title":"Synthesis and evaluation of some water-soluble prodrugs and derivatives of taxol with antitumor activity","volume":"35","author":"Mathew","year":"1992","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2019.04.013_bb0090","series-title":"Lexicomp Online","year":"2013"},{"issue":"2","key":"10.1016\/j.jconrel.2019.04.013_bb0095","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0006-8993(00)02910-3","article-title":"Description of a short-term Taxol-induced nociceptive neuropathy in rats","volume":"887","author":"Authier","year":"2000","journal-title":"Brain Res."},{"key":"10.1016\/j.jconrel.2019.04.013_bb0100","doi-asserted-by":"crossref","first-page":"456409","DOI":"10.1155\/2013\/456409","article-title":"Liposomal doxorubicin in the treatment of breast cancer patients: a review","volume":"2013","author":"Lao","year":"2013","journal-title":"J Drug Deliv."},{"issue":"4","key":"10.1016\/j.jconrel.2019.04.013_bb0105","first-page":"567","article-title":"Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation","volume":"2","author":"Rahman","year":"2007","journal-title":"Int. J. Nanomedicine"},{"issue":"3","key":"10.1016\/j.jconrel.2019.04.013_bb0110","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/annonc\/mdh097","article-title":"Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer","volume":"15","author":"O'Brien","year":"2004","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.jconrel.2019.04.013_bb0115","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s40265-016-0538-7","article-title":"Liposomal amphotericin B (AmBisome((R))): a review of the pharmacokinetics, pharmacodynamics, clinical experience and future directions","volume":"76","author":"Stone","year":"2016","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.jconrel.2019.04.013_bb0120","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.jconrel.2012.09.006","article-title":"Liposomal paclitaxel formulations","volume":"163","author":"Koudelka","year":"2012","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.jconrel.2019.04.013_bb0125","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jconrel.2008.05.024","article-title":"Receptor targeted polymers, dendrimers, liposomes: which nanocarrier is the most efficient for tumor-specific treatment and imaging?","volume":"130","author":"Saad","year":"2008","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2019.04.013_bb0130","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.neuroscience.2015.05.019","article-title":"Sensory neuron subpopulation-specific dysregulation of intracellular calcium in a rat model of chemotherapy-induced peripheral neuropathy","volume":"300","author":"Yilmaz","year":"2015","journal-title":"Neuroscience"},{"issue":"3","key":"10.1016\/j.jconrel.2019.04.013_bb0135","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0304-3959(01)00363-3","article-title":"A painful peripheral neuropathy in the rat produced by the chemotherapeutic drug, paclitaxel","volume":"94","author":"Polomano","year":"2001","journal-title":"Pain"},{"key":"10.1016\/j.jconrel.2019.04.013_bb0140","doi-asserted-by":"crossref","first-page":"240508","DOI":"10.1155\/2013\/240508","article-title":"The anticonvulsant enaminone E139 attenuates paclitaxel-induced neuropathic pain in rodents","volume":"2013","author":"Thangamani","year":"2013","journal-title":"Sci. World J."},{"issue":"6","key":"10.1016\/j.jconrel.2019.04.013_bb0145","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/fcp.12224","article-title":"Effect of subacute agomelatine treatment on painful diabetic neuropathy: involvement of catecholaminergic mechanisms","volume":"30","author":"Aydin","year":"2016","journal-title":"Fundam. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.jconrel.2019.04.013_bb0150","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/bja\/aex229","article-title":"Clinical and preclinical perspectives on Chemotherapy-Induced Peripheral Neuropathy (CIPN): a narrative review","volume":"119","author":"Flatters","year":"2017","journal-title":"Br. J. Anaesth."},{"issue":"4","key":"10.1016\/j.jconrel.2019.04.013_bb0155","first-page":"156","article-title":"Pathobiology of cancer chemotherapy-induced peripheral neuropathy (CIPN)","author":"Han","year":"2013","journal-title":"Front. Pharmacol."},{"issue":"12","key":"10.1016\/j.jconrel.2019.04.013_bb0160","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.pain.2014.09.020","article-title":"Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis","volume":"155","author":"Seretny","year":"2014","journal-title":"Pain"},{"issue":"1","key":"10.1016\/j.jconrel.2019.04.013_bb0165","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/bja\/aet208","article-title":"Neuropathic pain in cancer","volume":"111","author":"Fallon","year":"2013","journal-title":"Br. J. Anaesth."},{"issue":"12","key":"10.1016\/j.jconrel.2019.04.013_bb0170","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/nrneurol.2014.211","article-title":"Mechanism-based treatment for chemotherapy-induced peripheral neuropathic pain","volume":"10","author":"Sisignano","year":"2014","journal-title":"Nat. Rev. Neurol."},{"issue":"1","key":"10.1016\/j.jconrel.2019.04.013_bb0175","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/PL00007853","article-title":"Chemotherapy-induced peripheral neuropathy","volume":"249","author":"Quasthoff","year":"2002","journal-title":"J. Neurol."},{"key":"10.1016\/j.jconrel.2019.04.013_bb0180","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3389\/fnmol.2017.00174","article-title":"Pathophysiology of chemotherapy-induced peripheral neuropathy","volume":"10","author":"Starobova","year":"2017","journal-title":"Front. Mol. Neurosci."},{"issue":"2","key":"10.1016\/j.jconrel.2019.04.013_bb0185","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1254\/jphs.11062SC","article-title":"Comparison of peripheral neuropathy induced by standard and nanoparticle albumin\u2013bound paclitaxel in rats","volume":"117","author":"Yamashita","year":"2011","journal-title":"J. Pharmacol. Sci."},{"issue":"3","key":"10.1016\/j.jconrel.2019.04.013_bb0190","doi-asserted-by":"crossref","first-page":"569","DOI":"10.4143\/crt.2016.289","article-title":"An open-label, randomized, parallel, phase III trial evaluating the efficacy and safety of polymeric micelle-formulated paclitaxel compared to conventional cremophor EL-based paclitaxel for recurrent or metastatic HER2-negative breast cancer","volume":"49","author":"Park","year":"2017","journal-title":"Cancer Res. Treat."},{"key":"10.1016\/j.jconrel.2019.04.013_bb0195","series-title":"Paclitaxel Liposome for Injection [Package Insert in Chinese]","year":"2007"},{"issue":"4","key":"10.1016\/j.jconrel.2019.04.013_bb0200","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/00001813-200104000-00003","article-title":"Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel","volume":"12","author":"Meerum Terwogt","year":"2001","journal-title":"Anti-Cancer Drugs"},{"issue":"7","key":"10.1016\/j.jconrel.2019.04.013_bb0205","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1038\/sj.bjc.6602479","article-title":"NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel","volume":"92","author":"Hamaguchi","year":"2005","journal-title":"Br. J. Cancer"},{"issue":"18","key":"10.1016\/j.jconrel.2019.04.013_bb0210","doi-asserted-by":"crossref","first-page":"6149","DOI":"10.1523\/JNEUROSCI.6343-11.2012","article-title":"Targeting the overproduction of peroxynitrite for the prevention and reversal of paclitaxel-induced neuropathic pain","volume":"32","author":"Doyle","year":"2012","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jconrel.2019.04.013_bb0215","doi-asserted-by":"crossref","first-page":"e2702","DOI":"10.7717\/peerj.2702","article-title":"Gene expression profile of sodium channel subunits in the anterior cingulate cortex during experimental paclitaxel-induced neuropathic pain in mice","volume":"4","author":"Masocha","year":"2016","journal-title":"PeerJ"},{"issue":"1","key":"10.1016\/j.jconrel.2019.04.013_bb0220","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/ana.22382","article-title":"Muscle pain in models of chemotherapy-induced and alcohol-induced peripheral neuropathy","volume":"70","author":"Alvarez","year":"2011","journal-title":"Ann. Neurol."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365919302135?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365919302135?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:41:05Z","timestamp":1759160465000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365919302135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":44,"alternative-id":["S0168365919302135"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2019.04.013","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevention of paclitaxel-induced neuropathy by formulation approach","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2019.04.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}